Treatment outcomes of standard (high dose) cisplatin and non-standard chemotherapy for locally advanced head and neck cancer.

Muhammad AlamgeerAndrew ColemanLachlan McDowellCharles GiddingsAdnan SafdarElizabeth SigstonYang WangAshwin Subramaniam

Published in: Cancer reports (Hoboken, N.J.) (2022)

We demonstrated similar efficacy of lower dose weekly cisplatin and carboplatin/paclitaxel regimens and better safety profile of weekly cisplatin compared to standard HD cisplatin regimens for LA-HNSCC. Multicenter randomised control trials are required in HD cisplatin-ineligible patients.

Keyphrases

high dose
end stage renal disease
clinical trial
newly diagnosed
chronic kidney disease
low dose
squamous cell carcinoma
prognostic factors
stem cell transplantation
locally advanced